EU companies increasing R&D


Companies in the EU are increasing their investment in R&D, despite the difficult economic conditions, according to a report from the European Commission that looked at the global top 1500 R&D investors.

Investment rose by 8.9% in 2011, compared with a rise of 6.1% in 2010, putting the EU above the global average of 7.6% growth, but just below the US figure of 9% growth.

In absolute terms, the global pharma industry invested the most in R&D, over €90 billion (£72 billion) in 2011. But it was in second place within the EU, behind the automotive industry. Three drug makers nevertheless made it into the top ten EU investors in R&D: Sanofi at four, GlaxoSmithKline at five and AstraZeneca at eight.

But the Commission found the largest increases in investment in the banking, industrial engineering and automotive industries.

According to the report, the EU remains a highly attractive place for investment in R&D, thanks to: ‘developed markets with a sophisticated demand [so-called lead markets]; the quality and quantity of its pool of skilled labour; public support [of] R&D and the quality of its scientific and technological base’.


Related Content

Europe risks being outstripped by R&D rivals

26 October 2011 News Archive

news image

Investment in R&D by top European firms grew by 6 per cent last year, but competitors are growing faster

To leave or not to leave

31 May 2016 Comments

news image

Chris Leigh and Mike Galsworthy discuss their views on the EU referendum

Most Commented

Ethanol to butanol conversion shows sustainable potential

13 January 2016 Research

news image

Borrowed hydrogen chemistry drives reaction to obtain useful fuel from biomass

Injectable foam repairs bones

22 December 2015 Research

news image

Scientists say biomaterial could treat bone defects and diseases